Video

Integrating a Medical Oncologist Into Urology Practices

For High-Definition, Click

The CHAARTED trial studied the combination of androgen deprivation therapy (ADT) plus docetaxel therapy versus ADT alone in 790 patients diagnosed with hormone-sensitive metastatic prostate cancer. The combination resulted in a median overall survival of 57.6 months compared with 44 months in the ADT—alone arm (P = .0003).

Based on these and similar results, many urology practices are providing or considering providing intravenous chemotherapy therapy on-site for their cancer patients. In order to accomplish this, many urology practices will need to have a medical oncologist available on-site a few times a month to provide chemotherapy administration services, Gary M. Kirsh, MD, suggests. A number of urology groups around the country are incorporating medical oncology services.

It could be challenging to fully engage a medical oncologist in a urology practice, Sanford J. Siegel, MD, notes. However, having a medical oncologist on-site is in line with the integrated care model, and aids in further educating cancer patients about their options.

Related Videos
Rohan Garje, MD
Manmeet Ahluwalia, MD, MBA, FASCO
Anthony V. D'Amico, MD, PhD
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Timothy Yap, MBBS, PhD, FRCP
Sumanta Kumar Pal, MD, FASCO,